Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2024 · 10-Q
Revenue—
Net Income-$12.28M-$12.28MN/M vs Q1 2023 EPS Diluted-$0.25-$0.25— vs Q1 2023 Operating Income-$13,005,000N/M Operating Cash Flow$13,848,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Free Cash Flowderived$4,776,000N/M ended Mar 31, 2024 · filed May 15, 2024 · 45 d after period end